ModernaTX

Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a licensing deal with US firm Dragonfly Therapeutics. The agreement grants Dragonfly rights to use Nona Bio’s heavy chain only antibody discovery platform (HCAb) technology and develop antibodies according to Dragonfly’s designated targets. Financial details…